Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 302.75 EUR -1.06%
Market Cap: 2.5B EUR

VIRP's latest stock split occurred on Jul 30, 2002

The company executed a 4-for-1 stock split, meaning that for every share held, investors received 4 new shares.

The adjusted shares began trading on Jul 30, 2002. This was VIRP's 4th stock split, following the previous one in Nov 22, 1994.

Last Splits:
Jul 30, 2002
4-for-1
Nov 22, 1994
4-for-3
Feb 15, 1993
5-for-4
Jul 16, 1990
3275-for-3233
Pre-Split Price
N/A
Post-Split Price
124.1323
Before
After
Last Splits:
Jul 30, 2002
4-for-1
Nov 22, 1994
4-for-3
Feb 15, 1993
5-for-4
Jul 16, 1990
3275-for-3233

Virbac SA
Stock Splits History

VIRP Stock Splits Timeline
Jul 30, 2002
Jul 30, 2002
Split 4-for-1
x4
Pre-Split Price
N/A
Post-Split Price
124.1323
Before
After
Nov 22, 1994
Nov 22, 1994
Split 4-for-3
x1.3333333333333
Pre-Split Price
N/A
Post-Split Price
124.1323
Before
After
Feb 15, 1993
Feb 15, 1993
Split 5-for-4
x1.25
Pre-Split Price
N/A
Post-Split Price
124.1323
Before
After
Jul 16, 1990
Jul 16, 1990
Split 3275-for-3233
x1.0129910300031
Pre-Split Price
N/A
Post-Split Price
124.1323
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 15, 2025
Rover Metals Corp
F:4XO0
1-for-10
/10
0.0001 0.0005 EUR 0.05 0.05 EUR
Apr 15, 2025
S
Starbox Group Holdings Ltd
NASDAQ:STBX
1-for-14
/14
0.1426 1.9964 USD 1.8005 1.8005 USD
Apr 15, 2025
S
Scilex Holding Co
NASDAQ:SCLX
1-for-35
/35
0.1885 6.5975 USD 6.92 6.92 USD
Apr 15, 2025
Creative Media & Community Trust Corporation
NASDAQ:CMCT
1-for-25
/25
0.2057 5.1425 USD 5.24 5.24 USD
Apr 15, 2025
H
Hyungji Innovation and Creative Co Ltd
KOSDAQ:011080
549-for-451
x1.2172949002217
2210.0013 1815.502 KRW 2355 2355 KRW
Load More

Virbac SA
Glance View

Economic Moat
None
Market Cap
2.5B EUR
Industry
Pharmaceuticals

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

VIRP Intrinsic Value
360.68 EUR
Undervaluation 16%
Intrinsic Value
Price
Back to Top